Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding disorders that involve deficiency of factor VIII and von Willebrand factor. It is used in both prophylactic and on‑demand settings and may be administered before surgical procedures.

• Treatment of hemophilia A patients with factor VIII deficiency
• Management of von Willebrand disease of all types
• On‑demand therapy for acute bleeding episodes
• Prophylactic replacement to prevent recurrent bleeds
• Peri‑operative hemostatic support for surgical interventions
• Use in combination with other hemostatic agents when clinically required

Side effects of Haemate P may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common

• Mild headache or dizziness
• Low‑grade fever or chills
• Injection site erythema or swelling
• Transient nausea or abdominal discomfort
• Mild hypertension or blood pressure fluctuations

Serious

• Development of inhibitors (antibodies) against factor VIII or von Willebrand factor
• Severe allergic reactions, including anaphylaxis
• Thromboembolic events such as deep vein thrombosis
• Acute hemolytic reactions
• Renal impairment or acute kidney injury

Before using Haemate P, clinicians should consider several safety aspects to minimize risk.

• Assess patient history for previous inhibitor development or allergic reactions to plasma‑derived products
• Perform baseline screening for viral infections (e.g., HIV, hepatitis B/C) as the product is derived from human plasma
• Monitor for signs of thrombosis, especially in patients with pre‑existing risk factors
• Use caution in patients with renal or hepatic impairment; adjust monitoring accordingly
• Ensure proper aseptic technique to avoid contamination during intravenous administration
• Educate patients on recognizing early symptoms of inhibitor formation or hypersensitivity

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid

• Concurrent use of other factor concentrates without medical supervision, which may increase thrombotic risk
• High‑dose antifibrinolytic agents combined with factor replacement without careful monitoring
• Immunosuppressive therapies that could mask inhibitor development

Use with caution

• Anticoagulants (e.g., warfarin, direct oral anticoagulants) – monitor coagulation parameters closely
• Desmopressin (DDAVP) – may augment von Willebrand factor levels, requiring dose adjustments
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – increase bleeding risk, monitor gastrointestinal status
• Vaccinations – observe for potential immune reactions that could affect inhibitor formation